"Beike Holdings Limited", a Strategic Joint Venture With Bangkok-Based SiriCell Technologies, Inc., Will Support the Rapid Clinical Translation of Stem Cell Therapies & Regulatory Approval Outside of China
SHENZHEN, China, June 10 /PRNewswire-Asia/ -- Shenzhen Beike Biotechnology Co. Ltd. ("Beike") ( http://www.beikebiotech.com ), China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited ("Beike Holdings") a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers. The joint venture is actively constructing a regional network of world class cGMP stem cell manufacturing labs, distribution centers and storage banks to service and support its hospital training and clinical advisory services.
Beike's stem cells have been shown to be safe and effective in therapies based on direct clinical observation in the hospital setting. Beike Holdings will fund and oversee a series of comprehensive, multi-centered, adaptive Phase 1 and 2 clinical trials to advance the ongoing clinical validations of the safety and efficacy of Beike's stem cell therapies to patients throughout Southeast Asia.
In an effort to expand the availability of Beike's stem cell products for therapeutic applications to hospitals throughout the region, Beike Holdings is establishing subsidiary operations in major Asian urban centers. In the coming weeks Beike Holdings will announce a series of agreements with leading hospitals in Thailand, Malaysia, and the Philippines.
Beike Holdings Chief Executive Officer Alex Moffett commented, "The formation of Beike Holdings is an enormous leap forward in our efforts to expand and enhance international delivery capabilities for Beike's stem cell therapies. While Beike has established itself as the leading provider of stem cell therapies in China, building an international brand and network of facilities and hospital partners requires a truly international company. Beike's safe and effective therapies have already improved the lives of thousands patients, many of whom have travelled to China for treatment due to regulatory impediments in their home countries. Now, through Beike Holdings' expansion into Southeast Asia, we will be able to replicate that success on a larger scale."
Beike Holdings will maintain close ties to Beike's groundbreaking efforts in China, building on its deep experience in clinical innovations and the significant ongoing research at the company's new state-of-the-art Jiangsu Stem Cell Regenerative Medicine facility. At the same time the joint venture will remain independent and focused on its primary mission to develop new international markets, secure regulatory approvals and facilitate successful clinical translation of Beike's stem cell therapies. Beike Holdings and its expanding network will also provide new opportunities for international partnerships with medical and biotechnology innovators seeking rapid and affordable commercial outlets for their technologies.
Beike Chairman Dr. Sean Hu commented, "In China, our company and our therapies enjoy the highest levels of professional recognition and support-from provincial governments to respected research universities and hospitals. We have made great strides in building our reputation in the West, but it is our hope that, through Beike Holdings, we will improve our relationship with the Western scientific community as well. While cultural and geographic differences with the West will always exist, we share the same science. Beike Holdings will make that science available outside of China, and we believe that patients from around the world will view these therapies as more accessible and as a viable choice for many medical conditions for which no conventional treatment options are currently available."
About Beike Biotech:
Shenzhen Beike Biotechnology Co., Ltd. ("Beike") is China's leading biotechnology company whose scientists have been focused on the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of adult stem cell products from umbilical cord, cord blood, and bone marrow stem cells. Beike's stem cell therapies are administered by physicians at many leading hospitals throughout China.
Beike's unique processing technologies prepare the cells for use in treating a variety of serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury and optic nerve pathologies. Since Beike's founding, more than 8,000 patients have been treated with therapies using Beike's stem cells with no serious adverse effects or safety concerns, and with a high percentage of those patients reporting positive outcomes from the treatments.
Beike was founded with investment capital from Beijing University, Hong Kong University of Science and Technology, and from the Shenzhen Provincial Government and is headquartered in Shenzhen, with a flagship regenerative medicine facility at the China Medical City in Jiangsu Province.
About SiriCell Technologies: SiriCell Technologies, Inc. is an Asian-based company formed in 2007 as part of the rapidly advancing regenerative medicine industry. SiriCell is focused on increasing the availability and acceptance of adult stem cell technologies. The company's efforts involve the collection, production, and storage of adult stem cells, as well as the optimization and scientific validation of advanced stem cell therapies. The Company is also actively pursuing patent in-licensing opportunities for industry redefining stem cell technologies that will augment therapeutic efficacy and produce superior clinical results.
For more information, please contact: Ryan Knoll Tel: +1-213-880-4597 (USA)
SOURCE Shenzhen Beike Biotechnology Co., Ltd.